# A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

> **NCT06920771** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **HAL Allergy** · enrollment: 552 (estimated)

## Conditions studied

- House Dust Mite Allergy
- House Dust Mite Rhinitis

## Interventions

- **BIOLOGICAL:** PURETHAL Mites 50,000 AUeq/ml
- **BIOLOGICAL:** Biological/Vaccine: Placebo

## Key facts

- **NCT ID:** NCT06920771
- **Lead sponsor:** HAL Allergy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-08-31
- **Target enrollment:** 552 (ESTIMATED)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06920771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06920771, "A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06920771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*